Erlotinib and gefitinib, which bind selectively to ATP-binding sites of EGFR, have been so far the only two single-target TKIs, whereas lapatinib, the first TKI approved for breast cancer shows equal activity toward EGFR and HER2. The gene discussed is ERBB2; the disease is breast cancer.